Monopar Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -2,453 | -3,222 | -10,499 | -1,148 |
EBIT | -3,234 | -6,444 | -21,574 | -2,723 |
Net Income | -2,453 | -2,625 | -10,926 | -1,304,276 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -6,735,023 | -5,663 | -1,998 | -1,073 |
Cash | 39,501,936 | 39,711 | 45,816 | 6,020 |
Basic Shares | 6,998 | 6,987 | 37,902 | 3,520 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -15,586 | 429 | -10,515 | -9,079 |
EBIT | -31,748 | -8,401 | -10,536 | -9,127 |
Net Income | -15,586 | -8,402 | -10,494 | -9,079 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -6,404 | -7,858 | -7,228 | -7,317 |
Cash | 45,816 | 7,266 | 8,186 | 20,303 |
Basic Shares | 3,790 | 14,511 | 12,718 | 12,472 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.35 |
2025-03-31 | -$0.38 |
2024-12-31 | -$2.75 |
2024-09-30 | -$0.37 |
